<VariationArchive VariationID="807660" VariationName="NM_002693.3(POLG):c.2515del (p.Ala839fs)" VariationType="Deletion" Accession="VCV000807660" Version="3" RecordType="classified" NumberOfSubmissions="2" NumberOfSubmitters="2" DateLastUpdated="2024-06-23" DateCreated="2020-02-03" MostRecentSubmission="2023-12-30">
  <RecordStatus>current</RecordStatus>
  <Species>Homo sapiens</Species>
  <ClassifiedRecord>
    <SimpleAllele AlleleID="798691" VariationID="807660">
      <GeneList>
        <Gene Symbol="POLG" FullName="DNA polymerase gamma, catalytic subunit" GeneID="5428" HGNC_ID="HGNC:9179" Source="submitted" RelationshipType="within multiple genes by overlap">
          <Location>
            <CytogeneticLocation>15q26.1</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="15" Accession="NC_000015.10" start="89316320" stop="89334824" display_start="89316320" display_stop="89334824" Strand="-" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="15" Accession="NC_000015.9" start="89859535" stop="89878025" display_start="89859535" display_stop="89878025" Strand="-" />
          </Location>
          <OMIM>174763</OMIM>
        </Gene>
        <Gene Symbol="POLGARF" FullName="POLG alternative reading frame" GeneID="125316803" HGNC_ID="HGNC:56246" Source="calculated" RelationshipType="within multiple genes by overlap">
          <Location>
            <CytogeneticLocation>15q26.1</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="15" Accession="NC_000015.10" start="89316320" stop="89334824" display_start="89316320" display_stop="89334824" Strand="-" />
          </Location>
          <OMIM>620759</OMIM>
        </Gene>
      </GeneList>
      <Name>NM_002693.3(POLG):c.2515del (p.Ala839fs)</Name>
      <CanonicalSPDI>NC_000015.10:89321818:CCCC:CCC</CanonicalSPDI>
      <VariantType>Deletion</VariantType>
      <Location>
        <CytogeneticLocation>15q26.1</CytogeneticLocation>
        <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" forDisplay="true" AssemblyStatus="current" Chr="15" Accession="NC_000015.10" start="89321819" stop="89321819" display_start="89321819" display_stop="89321819" variantLength="1" positionVCF="89321818" referenceAlleleVCF="GC" alternateAlleleVCF="G" />
        <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="15" Accession="NC_000015.9" start="89865050" stop="89865050" display_start="89865050" display_stop="89865050" variantLength="1" referenceAllele="GC" alternateAllele="G" positionVCF="89865049" referenceAlleleVCF="GC" alternateAlleleVCF="G" />
      </Location>
      <ProteinChange>A839fs</ProteinChange>
      <HGVSlist>
        <HGVS Assembly="GRCh38" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000015.10" sequenceAccession="NC_000015" sequenceVersion="10" change="g.89321822del" Assembly="GRCh38">
            <Expression>NC_000015.10:g.89321822del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Assembly="GRCh37" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000015.9" sequenceAccession="NC_000015" sequenceVersion="9" change="g.89865053del" Assembly="GRCh37">
            <Expression>NC_000015.9:g.89865053del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="NG_008218.2" sequenceAccession="NG_008218" sequenceVersion="2" change="g.17977del">
            <Expression>NG_008218.2:g.17977del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001126131.2" sequenceAccession="NM_001126131" sequenceVersion="2" change="c.2515del">
            <Expression>NM_001126131.2:c.2515del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_001119603.1" sequenceAccession="NP_001119603" sequenceVersion="1" change="p.Ala839fs">
            <Expression>NP_001119603.1:p.Ala839fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_002693.3" sequenceAccession="NM_002693" sequenceVersion="3" change="c.2515del" MANESelect="true">
            <Expression>NM_002693.3:c.2515del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_002684.1" sequenceAccession="NP_002684" sequenceVersion="1" change="p.Ala839fs">
            <Expression>NP_002684.1:p.Ala839fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="LRG_765" sequenceAccession="LRG_765">
            <Expression>LRG_765:g.17977del</Expression>
          </NucleotideExpression>
        </HGVS>
      </HGVSlist>
      <XRefList>
        <XRef Type="rs" ID="1596352895" DB="dbSNP" />
      </XRefList>
    </SimpleAllele>
    <RCVList>
      <RCVAccession Title="NM_002693.3(POLG):c.2515del (p.Ala839fs) AND Sensory ataxic neuropathy, dysarthria, and ophthalmoparesis" Accession="RCV000995842" Version="5">
        <ClassifiedConditionList TraitSetID="1266">
          <ClassifiedCondition DB="MedGen" ID="C1843851">Sensory ataxic neuropathy, dysarthria, and ophthalmoparesis</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2018-11-08" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
      <RCVAccession Title="NM_002693.3(POLG):c.2515del (p.Ala839fs) AND Progressive sclerosing poliodystrophy" Accession="RCV003461301" Version="1">
        <ClassifiedConditionList TraitSetID="3716">
          <ClassifiedCondition DB="MedGen" ID="C0205710">Progressive sclerosing poliodystrophy</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2023-01-04" SubmissionCount="1">Likely pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
    </RCVList>
    <Classifications>
      <GermlineClassification DateLastEvaluated="2023-01-04" NumberOfSubmissions="2" NumberOfSubmitters="2" DateCreated="2020-02-03" MostRecentSubmission="2023-12-30">
        <ReviewStatus>criteria provided, multiple submitters, no conflicts</ReviewStatus>
        <Description>Pathogenic/Likely pathogenic</Description>
        <DescriptionHistory Dated="2023-12-29">
          <Description>Pathogenic</Description>
        </DescriptionHistory>
        <ConditionList>
          <TraitSet ID="3716" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="105" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">Mitochondrial DNA Depletion Syndrome 4A</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Mitochondrial DNA depletion syndrome 4A (Alpers type)</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Alpers disease</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Alpers diffuse degeneration of cerebral gray matter with hepatic cirrhosis</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Alpers progressive infantile poliodystrophy</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Poliodystrophia cerebri progressiva</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Progressive cerebral poliodystrophy</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Diffuse cerebral degeneration in infancy</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Neuronal degeneration of childhood with liver disease, progressive</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Infantile poliodystrophy</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Alpers Syndrome</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Preferred">Progressive sclerosing poliodystrophy</ElementValue>
                <XRef ID="Progressive+sclerosing+poliodystrophy/9168" DB="Genetic Alliance" />
                <XRef ID="20415001" DB="SNOMED CT" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Alpers-Huttenlocher Syndrome</ElementValue>
              </Name>
              <Symbol>
                <ElementValue Type="Preferred">MTDPS4A</ElementValue>
                <XRef Type="MIM" ID="203700" DB="OMIM" />
              </Symbol>
              <Symbol>
                <ElementValue Type="Alternate">PNDC</ElementValue>
                <XRef Type="MIM" ID="203700" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="keyword">POLG-Related Disorders</Attribute>
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="public definition">POLG-related disorders comprise a continuum of overlapping phenotypes that were clinically defined long before their molecular basis was known. Most affected individuals have some, but not all, of the features of a given phenotype; nonetheless, the following nomenclature can assist the clinician in diagnosis and management. Onset of the POLG-related disorders ranges from infancy to late adulthood. Alpers-Huttenlocher syndrome (AHS), one of the most severe phenotypes, is characterized by childhood-onset progressive and ultimately severe encephalopathy with intractable epilepsy and hepatic failure. Childhood myocerebrohepatopathy spectrum (MCHS) presents between the first few months of life and about age three years with developmental delay or dementia, lactic acidosis, and a myopathy with failure to thrive. Other findings can include liver failure, renal tubular acidosis, pancreatitis, cyclic vomiting, and hearing loss. Myoclonic epilepsy myopathy sensory ataxia (MEMSA) now describes the spectrum of disorders with epilepsy, myopathy, and ataxia without ophthalmoplegia. MEMSA now includes the disorders previously described as spinocerebellar ataxia with epilepsy (SCAE). The ataxia neuropathy spectrum (ANS) includes the phenotypes previously referred to as mitochondrial recessive ataxia syndrome (MIRAS) and sensory ataxia neuropathy dysarthria and ophthalmoplegia (SANDO). About 90% of persons in the ANS have ataxia and neuropathy as core features. Approximately two thirds develop seizures and almost one half develop ophthalmoplegia; clinical myopathy is rare. Autosomal recessive progressive external ophthalmoplegia (arPEO) is characterized by progressive weakness of the extraocular eye muscles resulting in ptosis and ophthalmoparesis (or paresis of the extraocular muscles) without associated systemic involvement; however, caution is advised because many individuals with apparently isolated arPEO at the onset develop other manifestations of POLG-related disorders over years or decades. Of note, in the ANS spectrum the neuropathy commonly precedes the onset of PEO by years to decades. Autosomal dominant progressive external ophthalmoplegia (adPEO) typically includes a generalized myopathy and often variable degrees of sensorineural hearing loss, axonal neuropathy, ataxia, depression, parkinsonism, hypogonadism, and cataracts (in what has been called "chronic progressive external ophthalmoplegia plus," or "CPEO+").</Attribute>
                <XRef ID="NBK26471" DB="GeneReviews" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="5783" />
                <XRef ID="5783" DB="Office of Rare Diseases" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301791</ID>
                <ID Source="BookShelf">NBK26471</ID>
              </Citation>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">29517884</ID>
                <ID Source="BookShelf">NBK487393</ID>
              </Citation>
              <XRef ID="726" DB="Orphanet" />
              <XRef ID="C0205710" DB="MedGen" />
              <XRef ID="MONDO:0008758" DB="MONDO" />
              <XRef Type="MIM" ID="203700" DB="OMIM" />
            </Trait>
          </TraitSet>
          <TraitSet ID="1266" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="4387" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">Sensory ataxic neuropathy-dysarthria-ophthalmoparesis syndrome</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Preferred">Sensory ataxic neuropathy, dysarthria, and ophthalmoparesis</ElementValue>
                <XRef ID="Sensory+ataxic+neuropathy%2C+dysarthria%2C+and+ophthalmoparesis/6505" DB="Genetic Alliance" />
                <XRef ID="MONDO:0011835" DB="MONDO" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Epilepsy, progressive myoclonic, type 5</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">SENSORY ATAXIC NEUROPATHY WITH MITOCHONDRIAL DNA DELETIONS, AUTOSOMAL RECESSIVE</ElementValue>
                <XRef Type="MIM" ID="607459" DB="OMIM" />
              </Name>
              <Symbol>
                <ElementValue Type="Alternate">EMP5</ElementValue>
              </Symbol>
              <Symbol>
                <ElementValue Type="Preferred">SANDO</ElementValue>
                <XRef Type="MIM" ID="607459" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="public definition">POLG-related disorders comprise a continuum of overlapping phenotypes that were clinically defined long before their molecular basis was known. Most affected individuals have some, but not all, of the features of a given phenotype; nonetheless, the following nomenclature can assist the clinician in diagnosis and management. Onset of the POLG-related disorders ranges from infancy to late adulthood. Alpers-Huttenlocher syndrome (AHS), one of the most severe phenotypes, is characterized by childhood-onset progressive and ultimately severe encephalopathy with intractable epilepsy and hepatic failure. Childhood myocerebrohepatopathy spectrum (MCHS) presents between the first few months of life and about age three years with developmental delay or dementia, lactic acidosis, and a myopathy with failure to thrive. Other findings can include liver failure, renal tubular acidosis, pancreatitis, cyclic vomiting, and hearing loss. Myoclonic epilepsy myopathy sensory ataxia (MEMSA) now describes the spectrum of disorders with epilepsy, myopathy, and ataxia without ophthalmoplegia. MEMSA now includes the disorders previously described as spinocerebellar ataxia with epilepsy (SCAE). The ataxia neuropathy spectrum (ANS) includes the phenotypes previously referred to as mitochondrial recessive ataxia syndrome (MIRAS) and sensory ataxia neuropathy dysarthria and ophthalmoplegia (SANDO). About 90% of persons in the ANS have ataxia and neuropathy as core features. Approximately two thirds develop seizures and almost one half develop ophthalmoplegia; clinical myopathy is rare. Autosomal recessive progressive external ophthalmoplegia (arPEO) is characterized by progressive weakness of the extraocular eye muscles resulting in ptosis and ophthalmoparesis (or paresis of the extraocular muscles) without associated systemic involvement; however, caution is advised because many individuals with apparently isolated arPEO at the onset develop other manifestations of POLG-related disorders over years or decades. Of note, in the ANS spectrum the neuropathy commonly precedes the onset of PEO by years to decades. Autosomal dominant progressive external ophthalmoplegia (adPEO) typically includes a generalized myopathy and often variable degrees of sensorineural hearing loss, axonal neuropathy, ataxia, depression, parkinsonism, hypogonadism, and cataracts (in what has been called "chronic progressive external ophthalmoplegia plus," or "CPEO+").</Attribute>
                <XRef ID="NBK26471" DB="GeneReviews" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="9998" />
                <XRef ID="9998" DB="Office of Rare Diseases" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301791</ID>
                <ID Source="BookShelf">NBK26471</ID>
              </Citation>
              <XRef ID="70595" DB="Orphanet" />
              <XRef ID="C1843851" DB="MedGen" />
              <XRef ID="MONDO:0011835" DB="MONDO" />
              <XRef Type="MIM" ID="607459" DB="OMIM" />
            </Trait>
          </TraitSet>
        </ConditionList>
      </GermlineClassification>
    </Classifications>
    <ClinicalAssertionList>
      <ClinicalAssertion ID="2268424" SubmissionDate="2020-01-21" DateLastUpdated="2020-02-03" DateCreated="2020-02-03">
        <ClinVarSubmissionID localKey="468-20200121" localKeyIsSubmitted="1" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV001150217" DateUpdated="2020-02-03" DateCreated="2020-02-03" Type="SCV" Version="1" SubmitterName="Institute of Human Genetics Munich, Klinikum Rechts Der Isar, TU MÃ¼nchen" OrgID="500240" OrganizationCategory="clinic" OrgAbbreviation="IHG-MRI-TUM" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2018-11-08">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="ModeOfInheritance">Autosomal recessive inheritance</Attribute>
        </AttributeSet>
        <AttributeSet>
          <Attribute Type="AssertionMethod">Classification criteria August 2017</Attribute>
          <Citation>
            <URL>https://submit.ncbi.nlm.nih.gov/ft/byid/inodbbrd/classification_criteria.pdf</URL>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>paternal</Origin>
              <Tissue>blood</Tissue>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>yes</AffectedStatus>
              <NumberTested>1</NumberTested>
              <Gender>female</Gender>
              <FamilyData PedigreeID="324-20200121" />
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="CompoundHeterozygote" integerValue="1" />
            </ObservedData>
            <ObservedData>
              <Attribute Type="SampleLocalID">324-20200121</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="POLG" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <Location>
            <SequenceLocation Assembly="GRCh37" Chr="15" alternateAllele="G" referenceAllele="GC" start="89865049" stop="89865050" />
          </Location>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="607459" Type="MIM" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB6902622</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="7851488" SubmissionDate="2023-12-07" DateLastUpdated="2023-12-30" DateCreated="2023-12-30">
        <ClinVarSubmissionID localKey="NM_002693.3:c.2515del|OMIM:203700" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV004205927" DateUpdated="2023-12-30" DateCreated="2023-12-30" Type="SCV" Version="1" SubmitterName="Baylor Genetics" OrgID="1006" OrganizationCategory="laboratory" OrgAbbreviation="BCM: BMGL" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2023-01-04">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Likely pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ACMG Guidelines, 2015</Attribute>
          <Citation>
            <ID Source="PubMed">25741868</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>unknown</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_002693.3:c.2515del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="203700" Type="MIM" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB13856327</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
    </ClinicalAssertionList>
    <TraitMappingList>
      <TraitMapping ClinicalAssertionID="7851488" TraitType="Disease" MappingType="XRef" MappingValue="203700" MappingRef="OMIM">
        <MedGen CUI="C0205710" Name="Progressive sclerosing poliodystrophy" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="2268424" TraitType="Disease" MappingType="XRef" MappingValue="607459" MappingRef="OMIM">
        <MedGen CUI="C1843851" Name="Sensory ataxic neuropathy, dysarthria, and ophthalmoparesis" />
      </TraitMapping>
    </TraitMappingList>
  </ClassifiedRecord>
</VariationArchive>

